✦ LIBER ✦

Denosumab treatment for 6 years in postmenopausal women with osteoporosis: The first 3 years of the freedom extension

✍ Scribed by D. Mellström⁎; J. Brown; H. Bone; R. Chapurlat; N. Franchimont; M. Brandi; E. Czerwiński; M.-A. Krieg; Z. Man; S. Radominski; H. Resch; J. Román; C. Roux; N. Daizadeh; M. Geller; S. Smith; R. Wagman; S. Cummings; S. Papapoulos

Book ID: 116325253
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 162 KB
Volume: 50
Category: Article
ISSN: 8756-3282
DOI: 10.1016/j.bone.2012.02.146

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Five years of denosumab exposure in wome

Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension

✍ Socrates Papapoulos; Roland Chapurlat; Cesar Libanati; Maria Luisa Brandi; Jacqu 📂 Article 📅 2012 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 256 KB 👁 1 views

The 3-year FREEDOM trial assessed the efficacy and safety of 60 mg denosumab every 6 months for the treatment of postmenopausal women with osteoporosis. Participants who completed the FREEDOM trial were eligible to enter an extension to continue the evaluation of denosumab efficacy and safety for up

Effects of 3 years of lasofoxifene

Effects of 3 years of lasofoxifene treatment on bone turnover markers in women with postmenopausal osteoporosis

✍ Richard Eastell; David M. Reid; Slobodan Vukicevic; Kristine E. Ensrud; Andrea Z 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 448 KB

The Effect of Three or Six Years of Deno

The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension

✍ Bone, Henry G.; Chapurlat, Roland; Brandi, Maria-Luisa; Brown, Jacques P.; Czerw 📂 Article 📅 2013 🏛 Endocrine Society 🌐 English ⚖ 312 KB

Outcome of investigations for postmenopa

Outcome of investigations for postmenopausal vaginal bleeding in women under the age of 50 years

✍ Nikolaos Burbos; Patrick Musonda; Simon G. Crocker; Edward P. Morris; Timothy J. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 142 KB

The effect of 3 versus 6 years of z

The effect of 3 versus 6 years of zoledronic acid treatment in osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)

✍ D.M. Black; I.R. Reid; J. Cauley; S. Boonen; F. Cosman; P. Leung; P. Lakatos; Z. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 146 KB

The change of BMD in postmenopausal oste

The change of BMD in postmenopausal osteoporosis women receiving an injection of rPTH 1-34 for 6 months and then no injection for 18 months

✍ Aijun Chao; Weihong Yu; Wei Hu; Li Wang; Decheng Kong Decheng 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Denosumab treatment for 6&#xa0;years in postmenopausal women with osteoporosis: The first 3&#xa0;years of the freedom extension

Denosumab treatment for 6 years in postmenopausal women with osteoporosis: The first 3 years of the freedom extension